skeletal myoblast cells
DESCRIPTION
Skeletal Myoblast Cells. Skeletal myoblasts. Derived from satellite cells in skeletal muscle With appropriate stimulus, satellite cells differentiate into muscle fibers Highly resistant to ischemia Do not contract spontaneously Do not differentiate into cardiomyocytes. Skeletal myoblasts. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Skeletal Myoblast Cells](https://reader035.vdocuments.net/reader035/viewer/2022072112/56812c58550346895d90e1db/html5/thumbnails/1.jpg)
Skeletal Myoblast Cells
![Page 2: Skeletal Myoblast Cells](https://reader035.vdocuments.net/reader035/viewer/2022072112/56812c58550346895d90e1db/html5/thumbnails/2.jpg)
2
Skeletal myoblasts
• Derived from satellite cells in skeletal muscle
• With appropriate stimulus, satellite cells differentiate into muscle fibers
• Highly resistant to ischemia
• Do not contract spontaneously
• Do not differentiate into cardiomyocytes
![Page 3: Skeletal Myoblast Cells](https://reader035.vdocuments.net/reader035/viewer/2022072112/56812c58550346895d90e1db/html5/thumbnails/3.jpg)
3
Human skeletal myoblasts after 3-wk in vitro culture period (magnification ×40)
Skeletal myoblasts
2-3 cm biopsy sample of thigh vastus lateralis (12-18 g) explanted under local anesthesia
Courtesy of Arshed A. Quyyumi, MD.
![Page 4: Skeletal Myoblast Cells](https://reader035.vdocuments.net/reader035/viewer/2022072112/56812c58550346895d90e1db/html5/thumbnails/4.jpg)
4
Before surgery After surgery
Menasché P et al. Lancet. 2001;357:279-80.
Skeletal myoblast transplantation in post-MI HF patients
![Page 5: Skeletal Myoblast Cells](https://reader035.vdocuments.net/reader035/viewer/2022072112/56812c58550346895d90e1db/html5/thumbnails/5.jpg)
5
Autologous skeletal myoblast injection for ischemic cardiomyopathy trial (MAGIC)
• Patients:– Moderate to severe LVSD referred
for CABG
• Cells:– Muscle Bx from thigh– Skeletal muscle myoblasts cultured
• Delivery:– Direct injection into scar at surgery
• Results:– Stopped early by DSMB due to low enrollment rate– Adverse event rate similar (25% cells vs 20% controls)– ICD Therapy in 15%– No improvement in LVEF by TTE (primary outcome)*– LVEF improved by SPECT– Highly significant dose-dependent LV size decrease
Cleland JGF et al. Eur J Heart Failure 2007;9:92-97.
PlaceboLow-Dose Myoblasts
High-Dose Myoblast P value
Patients enrolled
41 39 40
Patients injected
34 33 30
Change in LVEF (echo)*
+4.4% +3.4% +5.2% NS
Change in LVEF (nuc)
0 2% 3% <0.04
Change in LVEDD (mL)
+9 (-21 to 28)
-9 (-33 to 25)
-23 (-42 to 0)
0.006